Solid organ transplantation (SOT) recipients receive immunosuppressive therapy to avoid
rejection of the transplanted organ. Immunosuppressive therapy increases the risk of …

The development of noninvasive biomarkers that reflect the state of immunosuppression (IS)
remains an unmet need in liver transplantation (LT). Torque Teno virus (TTV) is a highly …

The main challenge of immunosuppressive therapy after solid organ transplantation is to
create a new immunological balance that prevents organ rejection and does not promote …

Balancing immunosuppression to prevent rejection in solid organ transplant (SOT)
recipients remains challenging. Torque teno virus (TTV), a commensal non‐pathogenic …

The nonpathogenic and ubiquitous torque teno virus (TTV) is associated with
immunosuppression in solid organ transplant recipients. Studies in kidney transplant …

Background Drug-induced immunosuppression following kidney transplantation is crucial to
prevent allograft rejection, but increases risk for infectious disease. Tailoring of drug dosing …

New reliable biomarkers are needed to improve individual risk assessment for post‐
transplant infection, acute graft rejection and other immune‐related complications after solid …

Background. Nonpathogenic torque teno viruses (TTVs) are highly prevalent in transplant
recipients and associated with immunosuppression. Studies in kidney transplant patients …

Potent immunosuppressive drugs have been introduced into clinical care for solid organ
transplant recipients. It is now time to guide these drugs on an individual level to optimize …

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established treatment
option for several hematological diseases. However, the first year post-transplantation is …